News
EDIT
5.65
+1.44%
0.08
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Seeking Alpha · 3d ago
Weekly Report: what happened at EDIT last week (0715-0719)?
Weekly Report · 4d ago
Following a 35% decline over last year, recent gains may please Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners
A total of 13 investors have a majority stake in Editas Medicine, Inc. (NASDAQ:EDIT) The company has a total of 51% ownership of the stock. Institutional investors own 72% of the company. This suggests the company is sensitive to the actions of institutional investors. The company is not owned by hedge funds. Editas medicine has a history of insider buying and selling of stock. You can see the insider purchasing of EditasMedicine shares from the past.
Simply Wall St · 07/16 19:52
Weekly Report: what happened at EDIT last week (0708-0712)?
Weekly Report · 07/15 09:11
Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Home Healthcare Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle. CRSP has achieved the regulatory approval for its gene editing technology as therapy for Severe Sickle Cell Disease and Thalassemia. The biotech company does not own the patent of its gene-editing technology. CRISPR Therapeutic AG has a high short interest and is only suitable for investors with higher risk tolerance.
Seeking Alpha · 07/13 14:00
Weekly Report: what happened at EDIT last week (0701-0705)?
Weekly Report · 07/08 09:11
EDITAS MEDICINE INC <EDIT.O>: EVERCORE ISI CUTS TARGET PRICE TO $7 FROM $15
Reuters · 07/02 10:34
Weekly Report: what happened at EDIT last week (0624-0628)?
Weekly Report · 07/01 09:11
Editas Medicine Board Member Resigns, Effective June 2024
TipRanks · 06/27 21:28
Weekly Report: what happened at EDIT last week (0617-0621)?
Weekly Report · 06/24 09:12
Selling Editas Medicine Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Editas Medicine, Inc. Insiders sold US$1.2m worth of stock over the last year. The average selling price of US$8.42 is lower than the current share price. In the last three months we saw more insider buying than selling at Editas Medicine. The company owns 0.4% of the company. Editas medicine's value has fallen 17% in the last week.
Simply Wall St · 06/20 11:00
Wall Street Analysts Are Neutral on Top Healthcare Picks
TipRanks · 06/19 05:10
Analysts’ Top Healthcare Picks: Editas Medicine (EDIT), Neurocrine (NBIX)
TipRanks has tracked 36,000 company insiders and found that Editas Medicine and Neurocrine have neutral ratings from analysts. The analysts are neither bullish nor bearish on the stocks. Editas medicine and neurocrine are two of the most popular names for insider trading.
TipRanks · 06/19 04:51
Unveiling 5 Analyst Insights On Editas Medicine
Editas Medicine is a clinical-stage genome editing company. The company has an average 12-month price target of $10.0. Editas Medicine's revenue growth over the past three months has been slower than its peers in the Health Care sector. The firm's net margin surpasses industry standards and the company has a strong financial performance.
Benzinga · 06/18 17:00
Editas Medicine Is Maintained at Perform by Oppenheimer
Dow Jones · 06/18 16:57
Editas Medicine Price Target Maintained With a $12.00/Share by Oppenheimer
Dow Jones · 06/18 16:57
Oppenheimer Maintains Perform on Editas Medicine, Maintains $12 Price Target
Benzinga · 06/18 16:46
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), GeoVax Labs (GOVX) and Editas Medicine (EDIT)
TipRanks · 06/18 12:20
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Taysha Gene Therapies (TSHA) and Editas Medicine (EDIT)
TipRanks · 06/18 09:40
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
NASDAQ · 06/17 12:13
More
Webull provides a variety of real-time EDIT stock news. You can receive the latest news about Editas Medicine Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDIT
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).